kshivets o. lung cancer surgery: prognosis

Click here to load reader

Post on 21-Apr-2017

1.242 views

Category:

Health & Medicine

1 download

Embed Size (px)

TRANSCRIPT

  • HOMEOSTASIS NETWORKS IN PROGNOSIS OF LUNG CANCER PATIENTS SURVIVALOleg Kshivets, M.D., Ph.D.Department of Surgery, Siauliai Cancer Center, LithuaniaThe 9th World Conference on Lung CancerTokyo, Japan, 2000

  • AbstractHomeostasis networks in prognosis of lung cancer patients survivalO.Kshivets. Siauliai Cancer Center, Siauliai, LithuaniaPurpose: The influence of homeostasis networks on 5-year survival (5YS) and life span (LS) of lung cancer (C) patients (LCP) after radical procedures was investigated.Methods: In a randomized trial (1970-1999) cases of radically operated and monitored consecutive 404 LCP (male=363, female=41; pneumonectomy=175, upper lobectomy=136, lower lobectomy=66, middle lobectomy=6, bilobectomy=21) with pathologic stage II-III (T1-N0-2M0; squamos cell C=263, adenocarcinoma=116, large cell C=25; stage II=111, stage III=293; T1=118, T2=187, T3=84, T4=15; N0=223, N1=97, N2=84; G1=100, G2=104, G3=200) were reviewed. 242 LCP (age=55.90.5 years; LS=2417.742.7 days; tumor diameter: D=4.10.1 cm) lived more than 5 years without any features of C progressing. 162 LCP (age=56.50.6 years; LS=576.030.6 days; D=4.70.2 cm) died because of relapses and generalization of C during the first 5 years after radical procedures. Variables selected for 5YS study were input levels of 46 blood and biochemic parameters, coagulogram, sex, age, TNMG, cell type, D. Representativeness of all samplings was reached by means of randomization based on unrepeated random selection. Multiple correspondence analysis (A), multi-factor clustering, A of variance, confirmatory factor A, structural equation modeling and Monte Carlo simulation were used to determine any significant overall regularities between 5YS (LS) and LCP homeostasis.Results: It was revealed that 5YS and LS of radically operated LCP (n=404) significantly depended on: 1) phase transition of early LC into invasive LC; 2) input level of blood cell subpopulations circuit; 3) ratio of C cell population quantity to blood cell subpopulations quantity in integral LCP organism (cell ratio factors: CRF); 4) LC characteristics (C cell population quantity, TNMG-system); 5) biochemic homeostasis; 6) hemostasis system; 7) anthropometric data. Structural equation modeling and Monte Carlo simulation confirmed significant overall networks between 5YS (LS) of LCP and blood cell subpopulations circuit (2=10485.5; k=169; T=4.747; P=0.000002), biochemic homeostasis (2=239.6; k=64; T=-3.64; P=0.0003), phase transition of early C into invasive C (2=5.540; k=1; T=3.711; P=0.0002), CRF (2=4017.8; k=43; T=4.377; P=0.00001), C characteristics (2=98.6; k=13; T=-4.635; P=0.000003); hemostasis system (2=211.6; k=34; T=6.814; P=0.000000); anthropometric data (2=157.3; k=8; T=3.50; P=0.0004).

  • Samplings:Lung Cancer Patients Lived More than 5 Years after Complete Resections.....242Lung Cancer Patients Died Because Generalization During First 5 Years after Complete Resections.....162In All...404

    *

  • Samplings:Adjuvant Chemoimmunoradiotherapy..54Postoperative Radiotherapy.......86Surgery Alone264In All...404

  • Radical Procedures:Pneumonectomy..175Upper/Lower Bilobectomy21Upper Lobectomy136Lower Lobectomy.66Middle Lobectomy.6Combined Procedures..49In All....404

    *

  • Main Problem of Analysis of Living Supersystems (e.g. Lung Cancer Patient Homeostasis): Phenomenon of Combinatorial ExplosionAverage Number of Routine Blood Parameters:.. 46Number of Possible Combination for Random Search:.... n!=46!=5.5e+57 Operation Time of The 7G Superteracomputer (1000TFLOPS) (The 21st Century).1.7e+35 Years

    *

  • BasisNP RP P n! n*n*2(e+n) or n log n n AI CSA+S+B SM

    *

  • Model Cancer Cells(Cr)--Human Killer Cells(Kl)r=Cr(1-KlCr/Kl);l=(KlCr/Kl)[25Cr/(4.189++2.5Cr)-Cr-1];

    *

  • Prognostic Role of Lung Cancer Diameter

    *

  • Clinicopathologic Nucloids of Lung Cancer Patients with N0-2, n=404

  • Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N0-2, n=404

  • Homeostasis Nucloids of Lung Cancer Patients with N0-2, n=404

  • Results of Cluster-Analysis of Homeostasis Data of Lung Cancer Patients with N0-2, n=404

  • Results of Correspondence Analysis of Pathologic Characteristics of Lung Cancer Patients with N0-2, n=404

  • Network-Model of Lung Cancer Patients with N0-2 (n=404)

  • Homeostasis Network-Model of Lung Cancer Patients with N0-2 (n=404)

  • Morphologic and Homeostasis Network-Model of Lung Cancer Patients with N0-2 (n=404)

  • Survival of Lung Cancer Patients with N0-2 (n=404)

  • Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N0-2, n=404

  • Logistic Regression Model of Lung Cancer Patients with N0-2, n=404

  • Survival of Lung Cancer Patients with N0-2 (n=404)

  • Survival of Lung Cancer Patients with N1-2 (n=181)

  • Cluster-Analysis of Data of Early and Invasive Lung Cancer Patients

  • Phase Transition Early Malignancy into Invasive Cancer

  • Results of Monte Carlo Simulation: Phase TransitionSurvival of LCP

  • Regularities between Dynamics Cancer Cell Population and Patient's Survival Rate

    *

  • Phase Transitions in System Homeostasis-Malignancy

    *

  • The Three Phase Transitions in the System Malignancy-Humans Organism

    *

  • Regression Models (Cell Ratio Factors--Life Span of LCP, n=162; 18th Degree Polynomial Fit): y=a+bx+cx2+dx 3+...

    *

  • Regression Models (Cell Ratio Factors--Life Span of LCP, n=162; 18th Degree Polynomial Fit): y=a+bx+cx2+dx 3+...

  • Regression Models (Cell Ratio Factors--Life Span of LCP, n=162; 15th Degree Polynomial Fit): y=a+bx+cx2+dx 3+...

  • Cell Ratio Factors in Prognosis of 5-Year Survival Lung Cancer Patients

    *

  • Results of Monte Carlo Simulation:Cell Ratio FactorsSurvival of LCP

    *

  • Results of Structural Equation Modeling

    *

  • Networks Between Lung Cancer Patients Survival and System Cancer- Homeostasis

    *

  • Superoncoprognosis-1.0

    *

  • Conclusions:5-year survival and life span of lung cancer patients (n=404) after complete resections significantly depended on: 1) phase transition of early cancer into invasive cancer; 2) input level of blood cell subpopulations circuit; 3) cell ratio factors: ratio of cancer cell population number to blood cell subpopulations number in integral lung cancer patient organism;4) cancer characteristics (cancer cell population number, TNMG-system); 5) the data of blood biochemical homeostasis;6) hemostasis system;7) anthropometric data.

  • Patents:1.Kshivets O.M. Method of Screening and Differential Diagnosis of Malignant Neoplasms. Patent from 27.04.92; N2045072: 28pp.2.Kshivets O.M. Method of Prognosis of Survival Rate of Radically Operated Patients with Malignant Neoplasms. Patent from 10.02.94; N2101704: 24pp. 3.Kshivets O.M. Method of Prognosis of Survival Rate of Non-Radically Operated Patients with Malignant Neoplasms. Patent from 14.03.94; N2104536: 10pp. 4.Kshivets O.M. Method of Early and Differential Immunodiagnosis of Malignant Neoplasms. Patent from 24.10.95; N2107290: 12pp. 5.Kshivets O.M. Method of Immunodiagnosis of Distant Metastases for Patients with Malignant Neoplasms. Patent from 06.10.95; N2107295: 8pp. 6.Kshivets O.M. Method of Immunodiagnosis of Generalization for Patients with Malignant Neoplasms. Patent from 09.10.95; N2107294: 12pp. 7.Kshivets O.M. Method of Immunodiagnosis of Early and Invasive Malignancy for Patients. Patent from 04.05.95: N2107293: 14pp. 8.Kshivets O.M. Method of Differential Diagnosis of Malignancy and Pre-Cancer or Non-Malignant Pathology. Patent from 08.11.94; N2114431: 18pp. 9. Kshivets O.M. Method of Measuring the Size of Malignant Neoplasms and Total Number of Malignant Cells in Oncopatients Organism Based on the Homeostasis Parameters. Patent from 04.05.95; N2135996: 8pp.

    *

  • Patents:10. Kshivets O.M. Method of Diagnosis of Distant Metastases for Patients with Malignant Neoplasms. Patent from 03.11.95; N2134878: 12pp. 11. Kshivets O.M. Method of Diagnosis of Generalization for Patients with Malignant Neoplasms. Patent from 20.10.95; N2132059: 12pp. 12. Kshivets O.M. Method of Diagnosis of Early and Invasive Malignancy for a Single Patient. Patent from 06.10.95; N2133466: 13pp. 13. Kshivets O.M. Method of Diagnosis of Malignant Neoplasms Metastasizing in Regional Lymphatic Nodules for a Concrete Patient. Patent from 29.09.95; N2131606: 10pp. 14. Kshivets O.M. Method of Measuring the Size of the Malignancy and Total Number of Malignant Cells in the Oncopatients Organism Based on the Immunogram. Patent from 04.05.95; N2135995: 9pp. 15. Kshivets O.M. Method of Immunodiagnosis of Regional Metastases for Patients with Malignant Neoplasms. Patent from 06.10.95; N2131607: 9pp.

    *

  • Address: Oleg Kshivets, M.D., Ph.D. Thoracic Surgeon Department of Surgery Siauliai Cancer CenterTilzes:42-16, Siauliai, LT78206, LithuaniaTel. (37041)416614Fax (37041)[email protected] [email protected]//:myprofile.cos.com/Kshivets

    *

    *

    *

    *

    *

    *

    *

    *

    *

    *

    *

    *

    *

    *

    *

    *

    *